A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Arthritis Care Medical Center, Somerset, New Jersey +2 locations
Conditions: Rheumatoid Arthritis
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
Recruiting
This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age. There will be two parts: Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo. Part II is an open label arm consis... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
08/01/2023
Locations: TKL Research, Inc.-Site Number:8400001, Fair Lawn, New Jersey
Conditions: Rheumatoid Arthritis